Neue Konzepte in der zielgerichteten systemischen Therapie des Mammakarzinoms

Zusammenfassung

Das Mammakarzinom ist gekennzeichnet durch eine ausgeprägte Heterogenität, deren Ausmaß in den vergangenen Jahren durch zahlreiche wissenschaftliche Arbeiten offenbar geworden ist. Bis dato wird das Mammakarzinom maßgeblich in 3 Subgruppen unterteilt, die eine luminale, eine Her-2-positive und eine tripel-negative Gruppe umfassen. Trotz umfangreicher Fortschritte in der Therapie von Patientinnen mit Mammakarzinom ist eine Optimierung der therapeutischen Konzepte notwendig und möglich. Während ein maßgeblicher Schwerpunkt in der Therapie luminaler und Her-2-positiver Tumoren auf der Vermeidung und Überwindung von Resistenzen liegt, steht die Entwicklung neuer, zielgerichteter Wirkstoffe für das tripelnegative Mammakarzinom im wissenschaftlichen Interesse.

Abstract

Breast cancer is characterized by a fundamental heterogeneity, the extent of which has been demonstrated in numerous scientific studies. Currently, breast cancer is divided into three major subgroups: luminal, Her-2 positive, and triple negative breast cancer. Despite considerable advances in the therapy of patients with breast cancer, further optimization of current therapeutic strategies is necessary and possible. While the therapy of luminal and Her-2 positive breast cancers focuses on preventing and overcoming tumoral resistance, research into triple negative breast cancer concentrates on developing and establishing novel targeted therapeutic agents.

molekulare Heterogenität - zielgerichtete Therapien - tripelnegativ - molekulare Subgruppen - kleine Moleküle

molecular heterogeneity - targeted therapies - triple negative - molecular subclass - small molecules

Literatur

• 1 Perou C M, Sorlie T, Eisen M B et al. Molecular portraits of human breast tumours.  Nature. 2000;  406 747-752
• 2 Sorlie T, Perou C M, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.  Proc Natl Acad Sci USA. 2001;  98 10869-10874
• 3 Liedtke C, Kiesel L. Basal/triple negative breast cancer.  Geburtsh Frauenheilk. 2009;  69 309-315
• 4 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
• 5 Forbes J F, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.  Lancet Oncol. 2008;  9 45-53
• 6 Coates A S, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.  J Clin Oncol. 2007;  25 486-492
• 7 Jassem J. Intergroup Exemestane Study mature analysis: overall survival data.  Anticancer Drugs. 2008;  19 (Suppl. 1) S3-S7
• 8 Mackey J R, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer [abstract].  Breast Cancer Res Treat. 2006;  100 (Suppl. 5) 3
• 9 Osborne K, Neven P, Dirix L et al. Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer [abstract].  Breast Cancer Res Treat. 2007;  106 (Suppl. 1) 2067
• 10 Cristofanilli M, Valero V, Mangalik A et al. A phase II multicenter, double-blind, randomised trial to compare anastrozole plus gefitinib with anastrozole plus placebo in post-menopausal women with hormone recptor positive metastatic breast cancer.  Proc Am Soc Clin Oncol. 2008;  26 15s
• 11 Goss P E, Ingle J N, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.  J Natl Cancer Inst. 2005;  97 1262-1271
• 12 Goss P E, Ingle J N, Pater J L et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.  J Clin Oncol. 2008;  26 1948-1955
• 13 Goss P E, Ingle J N, Martino S et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial [abstract].  Cancer Res. 2009;  69 (Suppl. 3) 487s
• 14 Valachis A, Mauri D, Polyzos N P et al. Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials.  Crit Rev Oncol Hematol. 2009; 
• 15 Di Leo A, Jerusalem G, Petruzelka L et al. CONFIRM: A phase III, randomized, parallel-group, trial comparing fulvestrant 250 mng vs. fulvestrant 500 mng in postmenopausal women with estrogen receptor-positive advanced breast cancer.  Cancer Res. 2009;  69 (Suppl.) 491s
• 16 Kuter I, Hegg R, Singer C et al. Fulvestrant 500 mg vs. 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer.  Breast Cancer Res Treat. 2007;  106 (Suppl.) S7
• 17 Macedo L F, Sabnis G J, Goloubeva O G et al. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.  Cancer Res. 2008;  68 3516-3522
• 18 Bergh J, Jönsson P E, Lidbrink E et al. First results from FACT – an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer.  Cancer Res. 2009;  69 (Suppl.) 490s
• 19 Slamon D J, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med. 2001;  344 783-792
• 20 Seidman A D, Fornier M N, Esteva F J et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.  J Clin Oncol. 2001;  19 2587-2595
• 21 Esteva F J, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.  J Clin Oncol. 2002;  20 1800-1808
• 22 Bendell J C, Domchek S M, Burstein H J et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.  Cancer. 2003;  97 2972-2977
• 23 Clayton A J, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.  Br J Cancer. 2004;  91 639-643
• 24 Scaltriti M, Rojo F, Ocana A et al. Expression of p 95 HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.  J Natl Cancer Inst. 2007;  99 628-638
• 25 Nahta R, Shabaya S, Ozbay T et al. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens.  Curr Pharmacogenomics Person Med. 2009;  7 263-274
• 26 Geyer C E, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.  N Engl J Med. 2006;  355 2733-2743
• 27 Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.  Breast Cancer Res Treat. 2008;  112 533-543
• 28 O'Shaughnessy J, Blackwell K L, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy.  J Clin Oncol. 2008;  26 (Suppl.) Abstr 2010
• 29 Blackwell K L, Burstein H J, Sledge G W et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy.  Cancer Res. 2009;  69 (Suppl.) 499s
• 30 Gelmon K A, Fumoleau P, Verma S et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy.  J Clin Oncol. 2008;  26 (Suppl.) Abstr. 1026
• 31 Cortés J, Baselga J, Petrella T et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer.  J Clin Oncol. 2009;  27 (Suppl.) Abstr. 1022
• 32 Baselga J, Cortes J, Fumoleau P et al. Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation.  Cancer Res. 2009;  69 (Suppl.) Abstr. 5114
• 33 Vogel C L, Burris H A, Limentani S et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results.  J Clin Oncol. 2009;  27 (Suppl.) Abstr. 1017
• 34 Krop I, LoRusso P, Miller K D et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients previously treated with lapatinib, trastuzumab, and chemotherapy.  Cancer Res. 2009;  69 (Suppl.) Abstr. 5090
• 35 Gluz O, Liedtke C, Gottschalk N et al. Triple-negative breast cancer – current status and future directions.  Ann Oncol. 2009;  20 1913-1927
• 36 Carey L A, Dees E C, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.  Clin Cancer Res. 2007;  13 2329-2334
• 37 Liedtke C, Mazouni C, Hess K R et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.  J Clin Oncol. 2008;  26 1275-1281
• 38 Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.  Breast Cancer Res Treat. 2009;  115 359-363
• 39 Gluz O, Nitz U A, Harbeck N et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.  Ann Oncol. 2008;  19 861-870
• 40 Tutt A, Robson M, Garber J E et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.  ASCO Meeting Abstracts. 2009;  27 (18S) CRA501
• 41 O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial.  ASCO Meeting Abstracts. 2009;  27 (18S) 3
• 42 Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.  J Clin Oncol. 2009;  27 4966-4972
• 43 Slamon D, Gomez H L, Kabbinavar F F et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer.  J Clin Oncol. 2008;  26 (Suppl.) Abstr. 1016
• 44 Baselga J, Roché H, Costa F et al. SOLTI0701: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when adminstered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC).  Cancer Res. 2009;  69 (Suppl.) 497s
• 45 Gradishar W J, Kaklamani V, Prasad Sahoo T et al. A double-blind, randomized, placebo-controlled, phase-2b study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as first-line therapy in patients with locally recurrent or metastatic breast cancer.  Cancer Res. 2009;  69 (Suppl.) 496s